Gregory Lemense, MD
Pulmonary Disease · Bozeman, MTNPI 1912904483
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Covidien LP accounts for 85.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $22,905 and has fallen 96.8% since, to $722 in 2025. Among pulmonary disease clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $625.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$34K
- Astrazeneca UK Limited$3K
- Medtronic$2K
- Philips North America LLC$66
- GSK$52
- Johnson & Johnson$51
- plus $158 from 6 others
What the payments were for
- Consulting fees$16,72842%
- Speaking & faculty fees$14,50337%
- Travel & lodging$6,61017%
- Food & beverage$1,5374%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 35 | $33,611 |
| Astrazeneca UK Limited | 2 | $3,003 |
| Medtronic | 6 | $2,437 |
| Philips North America LLC | 5 | $66 |
| GSK | 4 | $52 |
| Johnson & Johnson | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| AstraZeneca | 2 | $35 |
| Intuitive Surgical | 1 | $32 |
| United Therapeutics Corporation | 1 | $23 |
| Gilead | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$32,475
- ILLUMISITE$2,403
- Arcpoint$801
How this compares
$39,378 in reported general payments places this provider in the 95th percentile of 43 pulmonary disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EsbrietPirfenidone | 25 | $256,490 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $161,479 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $55,584 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $46,258 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $44,736 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $37,522 |
| Spiriva RespimatTiotropium Bromide | 35 | $22,713 |
| Serevent DiskusSalmeterol Xinafoate | 31 | $19,726 |
| Pirfenidone | 22 | $19,437 |
| DuleraMometasone/Formoterol | 47 | $16,409 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $14,881 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 78 | $10,879 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $10,119 |
| Sildenafil Citrate | 18 | $5,894 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Esbriet | $11 | $256,49025 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $52 | $248,671364 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $35 | $57,27787 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 pulmonary disease providers in Montana.
Other pulmonary disease in Bozeman
- Andrew GoldbergBozeman$6K
- Gyorgy MundruczoBozeman$1K
- Andrew SullivanBozeman$419
- Brittney WardBozeman$146
- Shauna BethelBozeman$101
- Megan SiskGreat Falls$20K
- John MazurGreat Falls$18K
- Bethany WeilerKalispell$14K
- Gabor VarjuGreat Falls$10K
- Dillon NolandKalispell$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.